DOI: 10.12890/2021_002265
Crohn’s Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab
Authors
Aasemab@hotmail.com
Keywords
Crohn’s disease, granuloma, vedolizumab, infliximabAbstract
Crohn’s disease is a chronic inflammatory bowel disease that can affect any part of the GI tract, which is frequently associated with extra-intestinal manifestations. Pulmonary parenchymal disease is very uncommon and usually considered to be debilitating and harder to diagnose. Pulmonary granulomas are rarely described in the literature as a complication of Crohn’s disease. Here, we present a patient with Crohn’s disease exacerbation who developed granulomatous lung disease under treatment with vedolizumab. Our case may add evidence to the emerging theory that gut-selective biologic agents could lead to upregulation of some pro-inflammatory factors leading to the evolution of pulmonary disease.
References
- Lu DG, Ji XQ, Liu X, Li HJ, Zhang CQ. Pulmonary manifestations of Crohn’s disease. World J Gastroenterol 2014;20(1):133–141.
- MacDermott RP, Nash GS, Nahm MH. Antibody secretion by human intestinal mononuclear cells from normal controls and inflammatory bowel disease patients. Immunol Invest 1989;18(1–4):449–457.
- Bienenstock J, McDermott M, Befus D, O’Neill M. A common mucosal immunologic system involving the bronchus, breast and bowel. Adv Exp Med Biol 1978;107:53–59.
- Chew MT, Chak E, Matsukuma K. A rare cause of pulmonary nodules. Case Rep Gastroenterol 2016;10(3):633–639.
- Lissner D, Glauben R, Allers K, Sonnenberg E, Loddenkemper C, Schneider T, et al. Pulmonary manifestation of Crohn’s disease developed under treatment with vedolizumab. Am J Gastroenterol 2018;113(1):146–148.